Bristol Myers gets positive EMA opinion for repotrectinib
Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...
Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story
Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
STAT2d
CAR-T promising for autoimmune disease while perhaps preserving fertility
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
2 Beaten-Down Dividend Stocks to Buy and Hold
2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...
BioSpace3d
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment
Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...
Yahoo Finance2d
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
NEW YORK (Reuters) - Bristol Myers Squibb (BMY) was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs ...